NCT01277705

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa & IPV Vaccines Administered Separately & Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents & Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 806 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the immunogenicity and reactogenicity of the candidate GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine when administered to healthy subjects aged ≥ 15 years in Germany and ≥ 18 years in France compared to Boostrix™ and inactivated poliovirus vaccine administered separately, and with Revaxis®

Conditions

• Tetanus
• Diphtheria
• Acellular Pertussis

Interventions

Type	Name	Description
BIOLOGICAL	GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine	Intramuscular, single
BIOLOGICAL	Boostrix™	Intramuscular, single dose
BIOLOGICAL	GSK Biologicals' IPV vaccine	Intramuscular, single dose
BIOLOGICAL	Revaxis®	Intramuscular, single dose

Timeline

• Start date: 2002-01-01
• Primary completion: 2002-04-01
• Completion: 2002-04-01
• First posted: 2011-01-17
• Last updated: 2016-09-07